ADC Therapeutics SA

ADCT

$3.64

Closing

▲5.81%

1D

▲119.28%

YTD

ADCT

BBG00Q6Q3RN0

Market cap

$350.13M

52 week high

$6.00

52 week low

$0.39

Volume

141,140

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$350.13M

Analysts' Rating

BUY

Price Target (Mean)

10.00

Total Analysts

6

P/E

Operating Margin

-186.19%

Beta

1.59

Revenue Growth (Annual)

-4.94%

52 week high

$6.00

52 week low

$0.39

Div. Yield

%

EPS Annual Growth

-45.63

Company Profile

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.